Nimustine slow release injection for treating noumenal tumour

A technology for sustained-release injections and sustained-release implants, which is used in antitumor drugs, liquid delivery, emulsion delivery, etc., can solve problems such as unclear effects, and achieve the effects of facilitating drug injection, reducing toxicity, and improving drug concentration.

Inactive Publication Date: 2007-02-28
JINAN KANGQUAN PHARMA TECH
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the effect ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] Put 90 mg of polylactic acid (PLA) with a molecular weight of 10,000 as pharmaceutical excipients into a container, add 100 ml of organic solvent to dissolve and mix with dichloromethane, add 10 mg of nimustine, shake again, and vacuum dry to remove the organic solvent. Shake well and vacuum dry to remove organic solvents. The dried drug-containing solid composition was freeze-pulverized into a micropowder containing 10% by weight nimustine, and then suspended in physiological saline containing 1.5% sodium carboxymethyl cellulose to prepare the corresponding suspension Sustained release injection, viscosity is 380cp-460cp (at 25℃-30℃). The subcutaneous release time is 30-35 days.

Embodiment 2

[0119] Put 75 mg of polylactic acid (PLA) with a molecular weight of 20,000 as pharmaceutical excipients into a container, add 100 ml of organic solvent to dissolve and mix with dichloromethane, add 25 mg of nimustine, shake again, and vacuum dry to remove the organic solvent. The dried solid composition is immediately shaped, and then irradiated to sterilize the dried solid composition to obtain an anti-cancer body implant containing 25% by weight of nimustine for curing solid tumors. The subcutaneous release time is 35-40 days.

Embodiment 3

[0121] Put 95 mg of polylactic acid (PLA) with a molecular weight of 40,000 as pharmaceutical excipients into a container, add 100 ml of methylene chloride as an organic solvent to dissolve and mix well, add 5 mg of Nimustine, shake again, and vacuum dry to remove the organic solvent. The dried solid composition is immediately shaped, and after being dispensed, it is ray sterilized to obtain an anti-cancer in vivo implant containing 100% by weight nimustine for curing solid tumors. The subcutaneous release time is 30-40 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to view more

Abstract

Disclosed is a Nimustine slow release injection for treating solid tumors, which comprises effective anticancer dose of Nimustine or the combination of Nimustine and its synergists (such as 5-FU, cisplatin or 06-benzyl guanine). The solid tumors include osteosarcoma, lymphoma, gastric carcinoma, cancer of pancreas, lung carcinoma, bladder carcinoma, hepatic carcinoma, breast cancer, esophagus cancer, intestinal cancer, thyroid carcinoma, and glioma. The viscosity of the slow release injection is 10-650cp (at 20-30 deg C), and the active anticancer constituents can also be made into slow release implanting agent. The slow release subsidiary materials mainly comprise bio-compactable and degradable macromolecular polymers, when locally dispensed on the tumor, the composition not only can lower down the whole body toxicity reaction of Nimustine, but also can selectively increase the tumor local medicinal concentration, the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can also be improved.

Description

(1) Technical field [0001] The invention relates to a sustained-release injection of nimustine for curing solid tumors, and belongs to the technical field of medicines. Mainly sustained-release injections and sustained-release implants. (2) Background technology [0002] Although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. In my country, about 1.6 million people suffer from cancer each year, and nearly 1.3 million people die from cancer, accounting for one-fifth of the total deaths. The incidence of cancer is increasing year by year and is showing a trend of younger age. According to data, in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. According to the latest statistics of the World Health Organization, the global cancer incidence will increase by 50% by 2020, and the number of cases will increase to 15 million. The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/10A61K31/505A61K47/34A61K31/513A61K31/282A61K31/52A61P35/00A61K47/26
Inventor 孔庆忠孙娟贺润平刘恩祥
Owner JINAN KANGQUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap